Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
New research on diagnosis and treatment of leukemia to be presented at 53rd ASH meeting

New research on diagnosis and treatment of leukemia to be presented at 53rd ASH meeting

Syndax announces data from entinostat phase 2 study on HL

Syndax announces data from entinostat phase 2 study on HL

Breakthroughs in hematopoietic cell transplantation to be presented at 53rd ASH meeting

Breakthroughs in hematopoietic cell transplantation to be presented at 53rd ASH meeting

SCRI to present findings of blood cancer trials at 53rd ASH annual meeting

SCRI to present findings of blood cancer trials at 53rd ASH annual meeting

New cancer research findings presented at 53rd ASH annual meeting

New cancer research findings presented at 53rd ASH annual meeting

Positive dose-escalation/expansion data from Array BioPharma's ARRY-614 Phase 1 MDS study

Positive dose-escalation/expansion data from Array BioPharma's ARRY-614 Phase 1 MDS study

Suppressing STARD9 protein could be a novel strategy to fight cancers

Suppressing STARD9 protein could be a novel strategy to fight cancers

Celgene announces results from azacitidine Phase 1 study on AML

Celgene announces results from azacitidine Phase 1 study on AML

PCI-32765 produces durable remissions in Phase I/II CLL clinical trial

PCI-32765 produces durable remissions in Phase I/II CLL clinical trial

New data from TetraLogic's TL32711 study on AML presented at 53rd ASH meeting

New data from TetraLogic's TL32711 study on AML presented at 53rd ASH meeting

People in Northern Ireland less likely to develop cancers

People in Northern Ireland less likely to develop cancers

Memgen to present ISF35 clinical trial data on CLL at 53rd ASH meeting

Memgen to present ISF35 clinical trial data on CLL at 53rd ASH meeting

Researchers discover molecular marker for immediate precursors of blood stem cells

Researchers discover molecular marker for immediate precursors of blood stem cells

Researchers discover potential target for cherubism

Researchers discover potential target for cherubism

Combination of MEK inhibitors and nilotinib can overcome CML resistance to targeted drug

Combination of MEK inhibitors and nilotinib can overcome CML resistance to targeted drug

Pharmacyclics, Janssen partner to develop and market PCI-32765 anti-cancer compound

Pharmacyclics, Janssen partner to develop and market PCI-32765 anti-cancer compound

FDA modifies requirements of Amgen's Nplate REMS Program

FDA modifies requirements of Amgen's Nplate REMS Program

GE Healthcare, UCSF collaborate for cord blood project

GE Healthcare, UCSF collaborate for cord blood project

Moffitt investigators to participate with 16 oral and 50 posters presentations at 53rd ASH meeting

Moffitt investigators to participate with 16 oral and 50 posters presentations at 53rd ASH meeting

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.